Navigation Links
Adjuvant combo shows potential for universal influenza vaccine
Date:6/8/2011

Researchers at National Jewish Health have discovered how to prime a second arm of the immune system to potentially boost influenza vaccine effectiveness. A combination of two adjuvants, chemicals used to boost the effectiveness of some vaccines, induced CD8, or killer, T cells to join antibodies in response to influenza infection. Since the killer T cells targeted a highly conserved protein that does not change from year to year, the adjuvant strategy suggests potential for a universal flu vaccine.

"Most vaccines protect against disease by boosting antibody protection," said lead author post-doctoral fellow Megan MacLeod, PhD. "We have shown that the two adjuvants work in concert to generate memory CD8 T cells, which can kill infected cells. We believe that this strategy of stimulating both the cellular and humoral immune responses holds promise for better vaccines."

Vaccines prepare the immune system to respond quickly to an infection with antibodies, Y-shaped molecules that neutralize or otherwise inactivate pathogens.

Aluminum salts, or alum, have been used for nearly a century as an adjuvant to boost the effectiveness of many vaccines. Surprisingly no one is sure even today exactly how it works. The only other adjuvant approved for use in the United States, monophosphoryl lipid A (MPL), is used by GlaxoSmithKline to boost the antibody response of some of its vaccines.

Dr. MacLeod, senior author Philippa Marrack, PhD, and their colleagues evaluated the responses of mice immunized with influenza vaccines containing no adjuvant, each adjuvant alone and both together. They engineered the vaccine so that any immune defense would be provided by killer T cells, not antibodies. Several weeks after the immunization, they infected the mice with influenza A virus.

They found that unvaccinated mice lost about 15 percent of their body weight in the first eight days after infection, then regained some of that weight by 20 days a
'/>"/>

Contact: William Allstetter
allstetterw@njhealth.org
303-398-1002
National Jewish Health
Source:Eurekalert

Page: 1 2

Related biology news :

1. Phase III study compared neoadjuvant therapy with lapatinib or trastuzumab for early breast cancer
2. Thalidomide shows efficacy as adjuvant therapy for hepatocellular carcinoma patients
3. Triple-combo drug shows promise against antiviral-resistant H1N1, UAB researcher says
4. UT Southwestern researchers use drug-radiation combo to eradicate lung cancer
5. Graphene and spintronics combo looks promising
6. Long-term study shows effect of climate change on animal diversity
7. New approach to treating cystic fibrosis lung infection shows promise
8. Research shows Brazilian acai berry antioxidants absorbed by human body
9. Wildfires cause ozone pollution to violate health standards, new study shows
10. New CU-Boulder study shows diversity decreases chances of parasitic disease
11. U of MN study shows link between gene variations and cancer survival
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... consumers to make ethical choices such as buying clothing ... on fair-trade coffee, and bringing their own bags when ... the Journal of Consumer Research , ethical consumption ... their emotions about unethical practices into action. , "Advocates ... environmental and human costs of the products they choose, ...
(Date:9/16/2014)...  Valencell, Inc., a leader in performance biometric data ... "Showcase Companies" representing North Carolina,s ... Venture Conference on September 16-17 th at the ... Raleigh, North Carolina . Valencell,s President Dr. ... the "Digital Health Spotlight Sector" on how the Company,s ...
(Date:9/16/2014)... of wild foods, autumn harks a season of bounty. ... luring intrepid collectors to woodlands in search of elusive ... in the allure of the treasure hunt, and their ... existence. But are the mushrooms which you are eating ... diverse yet vastly underdocumented although some estimates range ...
Breaking Biology News(10 mins):Why are consumers willing to spend more money on ethical products? 2Valencell, Inc. Selected as 'Showcase Company' at CED Tech Venture Conference 2014 2What's for dinner? Rapidly identifying undescribed species in a commercial fungi packet 2What's for dinner? Rapidly identifying undescribed species in a commercial fungi packet 3
... Over 50 leading experts will meet today in Brussels, ... cocoa flavanol research and the key findings of FLAVIOLA ... flavanols, their health benefits and potential applications. Members of ... of international researchers to review the outcomes of FLAVIOLA,s ...
... What cancerous conditions lead to what kinds of bacterial infections? ... benefit from pre-treatment with certain kinds of antibiotics. A University ... of the International Journal of Infectious Diseases shows ... are especially prevalent in patients with lung and GI ...
... that are socially isolated during a critical period of ... alcohol, found researchers at The University of Texas at ... the socially isolated rats. These effects, which are ... persist even after the rats are reintroduced into the ...
Cached Biology News:Recent breakthroughs in cocoa flavanol research discussed by European research consortium and expert panel 2Planning for bacteria in cancer patients may help hospitals fight infections 2Socially isolated rats are more vulnerable to addiction, report researchers 2Socially isolated rats are more vulnerable to addiction, report researchers 3
(Date:9/17/2014)... LAKE FOREST, California , 17 de ... BB: CYRX) ("la compañía"), principal proveedor mundial ... industria de las ciencias de la vida, ... una compañía de logística global con sede ... a su base de clientes Europa en ...
(Date:9/17/2014)... 2014 First antibacterial ... a truly novel class of anti-infective in ... a biopharmaceutical company developing a truly novel ... has secured £4.0m ($6.4m) to advance the ... a range of Gram-positive infections including  Clostridium ...
(Date:9/17/2014)... The Alliance for Clinical ... non-profit collaborative building a global system to enhance ... announced Phase 3 of its Site Accreditation and ... H. Kalali, Vice-President, Global Head, Neuroscience Center of ... and Quality Integration (CQI) Consulting will lead the ...
(Date:9/16/2014)... strap that can harvest energy from jaw movements has ... , It is hoped that the device can generate ... number of small-scale implantable or wearable electronic devices, such ... communication devices. , The first results of the device,s ... Publishing,s journal Smart Materials and Structures . , ...
Breaking Biology Technology:Cryoport contrata a Broekman Group para mejorar su apoyo operativo y logístico en Europa 2Cryoport contrata a Broekman Group para mejorar su apoyo operativo y logístico en Europa 3Cryoport contrata a Broekman Group para mejorar su apoyo operativo y logístico en Europa 4Cryoport contrata a Broekman Group para mejorar su apoyo operativo y logístico en Europa 5MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 2MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 3MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 4MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 5MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 6MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 7Global Standards Initiative for Clinical Research Sites Advances 2Global Standards Initiative for Clinical Research Sites Advances 3Global Standards Initiative for Clinical Research Sites Advances 4'Smart material' chin strap harvests energy from chewing 2
... ... in Arizona ,with State of the Art 3D Dedicated Neurology Suite, , ... (PRWEB) June 28, 2010 -- ... in the state of Arizona to adopt TrueVision® 3D Surgical Visualization, where multiple 3D ...
... ORLANDO, Fla. , June 26 Orexigen® Therapeutics, ... open-label study demonstrating that treatment with Contrave® resulted in significant improvements ... control of eating in overweight and obese patients with major depression. ... The ...
... 26, 2010 Amylin Pharmaceuticals, Inc. (Nasdaq: ... an integrated database of clinical studies that showed no ... (pramlintide acetate) injection use compared to a pooled comparator ... findings were presented at the 70th Annual Scientific Sessions ...
Cached Biology Technology:Cardon Children's Medical Center Adopts TrueVision 3D Surgical Visualization Platform for Department of Pediatric Neurosurgery 2Orexigen(R) Therapeutics Announces That Contrave(R) Reduced Depression Scores and Body Weight in Overweight and Obese Patients With Major Depression 2Orexigen(R) Therapeutics Announces That Contrave(R) Reduced Depression Scores and Body Weight in Overweight and Obese Patients With Major Depression 3Orexigen(R) Therapeutics Announces That Contrave(R) Reduced Depression Scores and Body Weight in Overweight and Obese Patients With Major Depression 4Orexigen(R) Therapeutics Announces That Contrave(R) Reduced Depression Scores and Body Weight in Overweight and Obese Patients With Major Depression 5Meta-Analysis of SYMLIN(R) Clinical Data Showed No Increased Risk of Cardiovascular Adverse Events Associated With SYMLIN Treatment in Patients With Type 2 Diabetes 2Meta-Analysis of SYMLIN(R) Clinical Data Showed No Increased Risk of Cardiovascular Adverse Events Associated With SYMLIN Treatment in Patients With Type 2 Diabetes 3Meta-Analysis of SYMLIN(R) Clinical Data Showed No Increased Risk of Cardiovascular Adverse Events Associated With SYMLIN Treatment in Patients With Type 2 Diabetes 4Meta-Analysis of SYMLIN(R) Clinical Data Showed No Increased Risk of Cardiovascular Adverse Events Associated With SYMLIN Treatment in Patients With Type 2 Diabetes 5Meta-Analysis of SYMLIN(R) Clinical Data Showed No Increased Risk of Cardiovascular Adverse Events Associated With SYMLIN Treatment in Patients With Type 2 Diabetes 6Meta-Analysis of SYMLIN(R) Clinical Data Showed No Increased Risk of Cardiovascular Adverse Events Associated With SYMLIN Treatment in Patients With Type 2 Diabetes 7
Dedicated 29.5" X 18" platforms for Stackable shakers. These platforms are optimized for a particular flask clip size and are sold with a full load of flask clips....
Request Info...
... BioPrime Plus Array CGH Genomic Labeling Systems ... reproducible labeling of genomic DNA samples for ... both indirect and direct labeling formats, the ... provide a flexible solution to your genomic ...
We offer solid and solution phase peptide synthesis including a whole range of modifications. Please send the details of your peptide synthesis need to info@rpeptide.com...
Biology Products: